심혈관질환 예방을 위한 고정용량 복합제 치료 = Fixed-dose combination therapy for cardiovascular prevention

다국어 초록 (Multilingual Abstract)

In patients with high cardiovascular risk, the number of drugs needed is often high, and this may decrease long-term adherence. Therefore, maintaining good adherence and reducing cardiovascular risk is currently an important issue in preventive cardiology. The combination of two different antihypertensive agents is reported to reduce blood pressure more than the doubling of a single agent. In addition, the prevalence of adverse events with two drugs is less than the sum of the number of events associated with each drug. The combination of renin-angiotensin system blockers with statins is a widely used regimen in cardiovascular prevention. Recent clinical trials using a fixed-dose combination of aspirin, statins, and angiotensin-converting enzyme inhibitors has revealed better adherence in the combination group than in the group with separately administered drugs. Interestingly, this benefit was more prominent in patients who were under-treated (less adherent) at baseline.

참고문헌 (Reference)

1 Law MR, "Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials" 326 : 1427-, 2003

2 Thom S, "Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial" 310 : 918-929, 2013

3 Webster R, "Effectiveness of fixed dose combination medication ('Polypills') compared with usual care in patients with cardiovascular disease or at high risk: a prospective, indi-vidual patient data meta-analysis of 3140 patients in six coun-tries" 205 : 147-156, 2016

4 Selak V, "Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care" 348 : g3318-, 2014

5 Wald DS, "Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials" 122 : 290-300, 2009

6 장지영, "Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients" 대한심장학회 45 (45): 225-233, 2015

7 Patel A, "A pragmatic randomized trial of a Polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk" 22 : 920-930, 2015

8 Castellano JM, "A Polypill strategy to improve adherence: results from the FOCUS project" 64 : 2071-2082, 2014

9 Mancia G, "2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)" 34 : 2159-2219, 2013

10 Fihn SD, "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the Ameri-can College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons" 126 : 3097-3137, 2012